title: Effect of fosinopril on chemerin and VEGF expression in diabetic nephropathy rats.
abstract: As the most common and severe complication of diabetes, diabetic nephropathy (DN) has been known to be related with angiotensin converting enzyme inhibitor (ACEI), which can reduce proteinuria and protect renal function. This study analyzed the effect of ACEI analog-fosinopril-on the expression of chemerin and vascular epithelial growth factor (VEGF), in an attempt to reveal the mechanism of ACEI analog on renal protection. A total of 45 SD rats were induced by sreptozotocin for diabetes and were given fosinopril via intragastric cannulation for 12 weeks. After sacrifice, serum and renal chemerin and VEGF contents were quantified by enzyme linked immunosorbent assay (ELISA) and Western blot method, in addition to biochemical laboratory examinations. In diabetic model rats, blood glucose, creatinine, urea nitrogen, 24-hour urinary protein, chemerin and VEGF protein contents were all significantly elevated when compared to those in control group (P<0.05). After fosinopril treatment, blood creatinine, urea nitrogen, 24-hour urinary protein, Chemerin and VEGF protein concentrations were significantly depressed (P<0.05 compared to model group). Positive relationships existed between renal chemerin, VEGF and urea protein levels. Fosinopril may protect renal tissues in diabetes by suppressing chemerin and VEGF protein expression.
authors.affiliation: Department of Internal Medicine, The Eastern Hospital of First Affiliated Hospital, Sun Yat-Sen University Guangzhou 510700, China.
authors.forename: Haifeng
authors.initials: H
authors.lastname: Huang
authors.affiliation: Department of Pharmacy, The Eastern Hospital of First Affiliated Hospital, Sun Yat-Sen University Guangzhou 510700, China.
authors.forename: Liping
authors.initials: L
authors.lastname: Hu
authors.affiliation: Department of Internal Medicine, The Eastern Hospital of First Affiliated Hospital, Sun Yat-Sen University Guangzhou 510700, China.
authors.forename: Jiancong
authors.initials: J
authors.lastname: Lin
authors.affiliation: Department of Internal Medicine, The Eastern Hospital of First Affiliated Hospital, Sun Yat-Sen University Guangzhou 510700, China.
authors.forename: Xiaoxiao
authors.initials: X
authors.lastname: Zhu
authors.affiliation: Department of Internal Medicine, The Eastern Hospital of First Affiliated Hospital, Sun Yat-Sen University Guangzhou 510700, China.
authors.forename: Weiling
authors.initials: W
authors.lastname: Cui
authors.affiliation: Department of Internal Medicine, The Eastern Hospital of First Affiliated Hospital, Sun Yat-Sen University Guangzhou 510700, China.
authors.forename: Wenming
authors.initials: W
authors.lastname: Xu
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D015153:Blotting, Western; D018925:Chemokines / Q000096:biosynthesis* / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental; D003928:Diabetic Nephropathies / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D017328:Fosinopril / Q000494:pharmacology*; D036341:Intercellular Signaling Peptides and Proteins / Q000096:biosynthesis*; D007668:Kidney / Q000187:drug effects*; D008297:Male; D051381:Rats; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis* / Q000187:drug effects
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D018925:Chemokines; D036341:Intercellular Signaling Peptides and Proteins; C478630:RARRES2 protein, human; D042461:Vascular Endothelial Growth Factor A; D017328:Fosinopril
keywords: Fosinopril; VEGF; chemerin; diabetic nephropathy